Among the entire study cohort, there were 30 patients with tumour PD-L1 expression levels equal to or greater than 50%, 10 of whom received single-agent immunotherapy; these had a short time to progression, and 5/10 had progressive disease as the best response. Here, CD274 is linked to neoplasm.